JP7329260B2 - ボロン酸誘導体およびその治療的使用 - Google Patents

ボロン酸誘導体およびその治療的使用 Download PDF

Info

Publication number
JP7329260B2
JP7329260B2 JP2020557178A JP2020557178A JP7329260B2 JP 7329260 B2 JP7329260 B2 JP 7329260B2 JP 2020557178 A JP2020557178 A JP 2020557178A JP 2020557178 A JP2020557178 A JP 2020557178A JP 7329260 B2 JP7329260 B2 JP 7329260B2
Authority
JP
Japan
Prior art keywords
compound
mmol
compounds
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020557178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522167A (ja
JPWO2019204419A5 (enExample
Inventor
ラジャ ケー． レディ，
スコット ジェイ． ヘッカー，
Original Assignee
キューペックス バイオファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キューペックス バイオファーマ， インコーポレイテッド filed Critical キューペックス バイオファーマ， インコーポレイテッド
Publication of JP2021522167A publication Critical patent/JP2021522167A/ja
Publication of JPWO2019204419A5 publication Critical patent/JPWO2019204419A5/ja
Priority to JP2023129305A priority Critical patent/JP7651203B2/ja
Application granted granted Critical
Publication of JP7329260B2 publication Critical patent/JP7329260B2/ja
Priority to JP2025035562A priority patent/JP2025083398A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020557178A 2018-04-20 2019-04-17 ボロン酸誘導体およびその治療的使用 Active JP7329260B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023129305A JP7651203B2 (ja) 2018-04-20 2023-08-08 ボロン酸誘導体およびその治療的使用
JP2025035562A JP2025083398A (ja) 2018-04-20 2025-03-06 ボロン酸誘導体およびその治療的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862660729P 2018-04-20 2018-04-20
US62/660,729 2018-04-20
PCT/US2019/027844 WO2019204419A1 (en) 2018-04-20 2019-04-17 Boronic acid derivatives and therapeutic uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023129305A Division JP7651203B2 (ja) 2018-04-20 2023-08-08 ボロン酸誘導体およびその治療的使用

Publications (3)

Publication Number Publication Date
JP2021522167A JP2021522167A (ja) 2021-08-30
JPWO2019204419A5 JPWO2019204419A5 (enExample) 2022-04-08
JP7329260B2 true JP7329260B2 (ja) 2023-08-18

Family

ID=68240303

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020557178A Active JP7329260B2 (ja) 2018-04-20 2019-04-17 ボロン酸誘導体およびその治療的使用
JP2023129305A Active JP7651203B2 (ja) 2018-04-20 2023-08-08 ボロン酸誘導体およびその治療的使用
JP2025035562A Pending JP2025083398A (ja) 2018-04-20 2025-03-06 ボロン酸誘導体およびその治療的使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023129305A Active JP7651203B2 (ja) 2018-04-20 2023-08-08 ボロン酸誘導体およびその治療的使用
JP2025035562A Pending JP2025083398A (ja) 2018-04-20 2025-03-06 ボロン酸誘導体およびその治療的使用

Country Status (9)

Country Link
US (2) US12016868B2 (enExample)
EP (1) EP3781576B1 (enExample)
JP (3) JP7329260B2 (enExample)
CN (1) CN112424209A (enExample)
AU (1) AU2019256351B2 (enExample)
CA (1) CA3097127A1 (enExample)
TW (1) TW201945005A (enExample)
WO (1) WO2019204419A1 (enExample)
ZA (1) ZA202006377B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023159197A (ja) * 2018-04-20 2023-10-31 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026582A1 (en) 2016-06-30 2018-01-04 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN113880871B (zh) * 2020-10-16 2022-08-23 中国科学院兰州化学物理研究所 一种饱和单硼类化合物的制备方法
EP4304581A1 (en) 2021-03-08 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
BR112023018196A2 (pt) 2021-03-09 2023-12-12 Lilly Co Eli Uso de mevidalen e outros moduladores alostéricos positivos d1 para retardar a progressão da doença de parkinson
TW202404610A (zh) * 2022-06-24 2024-02-01 大陸商瑞石生物醫藥有限公司 一種硼酸酯衍生物的結晶、其製備方法及用途
US20250099495A1 (en) * 2023-09-22 2025-03-27 City University Of Hong Kong Methods of inhibiting klebsiella pneumoniae carbapenemase-2
WO2025119216A1 (zh) * 2023-12-04 2025-06-12 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其制备方法和应用
CN119119096B (zh) * 2024-09-09 2025-09-16 郑州药领医药科技有限公司 一种4-((4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)甲基)哌啶-1-甲酸叔丁酯的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505619A (ja) 2013-01-04 2016-02-25 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018005662A1 (en) 2016-06-30 2018-01-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (fr) 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4822786A (en) 1986-07-01 1989-04-18 Kaken Pharmaceutical Co., Ltd. Cephalosporin compounds, and antibacterial agents
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
JP2002504122A (ja) 1997-06-13 2002-02-05 ノースウエスタン ユニバーシティー ベータラクタマーゼ阻害剤及びその使用方法
WO2000035905A1 (en) 1998-12-16 2000-06-22 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
IL148818A0 (en) 1999-09-25 2002-09-12 Smithkline Beecham Plc Piperazine derivatives as 5-ht1b
CA2388077A1 (en) 1999-10-28 2001-05-03 James M. Balkovec Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
WO2002022137A1 (en) 2000-09-12 2002-03-21 Shoichet Brian K β-LACTAM ANALOGS AND USES THEREFOR
AU1261402A (en) 2000-09-14 2002-03-26 Naeja Pharmaceutical Inc 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
AU2002243508A1 (en) 2001-01-10 2002-07-24 Bristol-Myers Squibb Company Patent Department Alpha-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
AU2002360732A1 (en) 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
EP1550657A4 (en) 2002-09-11 2009-12-30 Kureha Corp AMINO COMPOUNDS AND THEIR USE
EP3412696A1 (en) 2002-10-30 2018-12-12 Sumitomo Chemical Company, Limited High-molecular compounds and polymer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
MXPA05006798A (es) 2002-12-20 2006-03-09 Migenix Corp Ligandos de adenina nucleotido translocasa (ant) y composiciones y metodos relacionados a estos.
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
WO2005033090A1 (ja) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited 芳香族化合物
ES2288270T3 (es) 2003-10-10 2008-01-01 Pfizer Products Incorporated 2h-(1,2,4)triazolo(4,3-a)pirazinas sustituidas como inhibidores de gsk-3.
BRPI0416444B8 (pt) 2003-11-12 2021-05-25 Chiesi Farm Spa composto de ácido borônico heterocíclico, composição farmacêutica, e, combinação farmacêutica compreendendo o mesmo
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
KR101337045B1 (ko) 2005-02-16 2013-12-05 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
CA2680693A1 (en) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
US9184428B2 (en) 2005-03-15 2015-11-10 Uchicago Argonne Llc Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
DK2484680T3 (da) 2005-12-07 2013-09-08 Basilea Pharmaceutica Ag Nyttige kombinationer af monolactam-antibiotika med beta-lactamase-inhibitorer
KR20150013941A (ko) 2006-02-16 2015-02-05 아나코르 파마슈티칼스 인코포레이티드 항염증제로서 보론함유 소분자
WO2008039420A2 (en) 2006-09-27 2008-04-03 Merck & Co., Inc. Novel inhibitors of beta-lactamase
BRPI0809147A2 (pt) 2007-03-23 2014-08-26 Basilea Pharmaceutica Ag Medicamentos combinados para tratamento de infecções bacterianas
GB0719366D0 (en) 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
AU2008321443A1 (en) 2007-11-13 2009-05-22 Novartis Ag Beta-lactamase inhibitors
ME02089B (me) 2008-01-18 2014-04-30 Merck Sharp & Dohme Inhibitori beta-laktamaze
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2009140309A2 (en) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2273882A4 (en) 2008-05-13 2011-07-13 Poniard Pharmaceuticals Inc BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER AND NEURODEEGENERATIVE DISEASES
WO2010075286A1 (en) 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
EP2406233B1 (en) 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
AR076667A1 (es) 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
JP2012529511A (ja) 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
RU2012107163A (ru) 2009-07-28 2013-09-10 Анакор Фармасьютикалз, Инк. Тризамещенные борсодержащие молекулы
US20120329770A1 (en) 2010-02-26 2012-12-27 Gary Igor Dmitrienko Cephalosporin derivatives useful as beta-lactamase inhibitors and compositions and methods of use thereof
CN102892291A (zh) 2010-03-31 2013-01-23 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
US8822516B2 (en) 2010-06-10 2014-09-02 Technion Research & Development Foundation Limited Process for the preparation of iodides
CN103180328B (zh) 2010-08-10 2016-10-26 莱姆派克斯制药公司 环硼酸酯衍生物及其治疗用途
JP5909239B2 (ja) 2010-10-26 2016-04-26 マーズ インコーポレイテッド アルギナーゼ阻害剤としてのボロネート
AU2011329486A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
CN102320960A (zh) 2011-08-02 2012-01-18 安徽东健化工科技有限公司 一种6-氟水杨酸的制备方法
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
CN104321060B (zh) 2011-12-22 2018-08-07 阿雷斯贸易股份有限公司 α-氨基硼酸衍生物，选择性免疫蛋白酶体抑制剂
CA2862710A1 (en) 2012-01-09 2013-07-18 University Of Tromso Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP6403219B2 (ja) 2012-12-07 2018-10-10 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
WO2014107535A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) * 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
SG11201506875YA (en) 2013-03-15 2015-09-29 Intrexon Corp Boron-containing diacylhydrazines
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
HRP20191932T1 (hr) 2014-05-05 2020-01-24 Rempex Pharmaceuticals, Inc. Sinteza boronatnih soli i njihove uporabe
EP3145936B1 (en) 2014-05-19 2020-09-30 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2950917C (en) 2014-06-11 2022-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10206937B2 (en) * 2014-07-01 2019-02-19 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016116892A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Antibacterial compositions
EP3285776B1 (en) 2015-04-24 2022-12-21 Melinta Therapeutics, Inc. Dosage regimen of vaborbactam and meropenem for treating bacterial infections in subjects with reduced renal function
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2017295866A1 (en) 2016-07-14 2019-01-17 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
PT3512851T (pt) 2016-09-16 2022-10-11 Entasis Therapeutics Ltd Compostos inibidores de beta-lactamase
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
KR102626967B1 (ko) 2017-10-11 2024-01-18 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 이의 합성
WO2019093450A1 (ja) 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
WO2019204419A1 (en) * 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
SG11202105505TA (en) 2018-11-29 2021-06-29 Venatorx Pharmaceuticals Inc Combination compositions comprising a beta-lactamase inhibitor and uses thereof
HUE072159T2 (hu) 2019-06-19 2025-10-28 Qpex Biopharma Inc Bórsav-származékok és terápiás alkalmazásuk
JP7673052B2 (ja) 2019-08-29 2025-05-08 アリクサ ファーマシューティカルズ、インコーポレイテッド 細菌感染症を処置するためのベータラクタム抗生物質およびアビバクタム誘導体の経口投与される組合せ

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505619A (ja) 2013-01-04 2016-02-25 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018005662A1 (en) 2016-06-30 2018-01-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023159197A (ja) * 2018-04-20 2023-10-31 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
JP7651203B2 (ja) 2018-04-20 2025-03-26 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用

Also Published As

Publication number Publication date
JP2025083398A (ja) 2025-05-30
JP2021522167A (ja) 2021-08-30
EP3781576C0 (en) 2024-06-12
EP3781576A1 (en) 2021-02-24
US12016868B2 (en) 2024-06-25
TW201945005A (zh) 2019-12-01
EP3781576B1 (en) 2024-06-12
US20240307422A1 (en) 2024-09-19
EP3781576A4 (en) 2022-03-02
CA3097127A1 (en) 2019-10-24
BR112020021356A2 (pt) 2021-01-19
JP7651203B2 (ja) 2025-03-26
CN112424209A (zh) 2021-02-26
AU2019256351A1 (en) 2020-11-12
AU2019256351B2 (en) 2024-02-29
JP2023159197A (ja) 2023-10-31
ZA202006377B (en) 2024-02-28
WO2019204419A1 (en) 2019-10-24
US20210361682A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
JP7329260B2 (ja) ボロン酸誘導体およびその治療的使用
US11999759B2 (en) Boronic acid derivatives and therapeutic uses thereof
KR101987091B1 (ko) 고리형 보론산 에스터 유도체 및 이의 치료상 용도
EP3145936B1 (en) Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) Boronic acid derivatives and therapeutic uses thereof
CN104994844A (zh) 硼酸衍生物及其治疗用途
US10662205B2 (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
HK40045753A (en) Boronic acid derivatives and therapeutic uses thereof
HK40045753B (en) Boronic acid derivatives and therapeutic uses thereof
BR112020021356B1 (pt) Derivados de ácido borônico e usos terapêuticos dos mesmos
HK40000809B (en) Boronic acid derivatives and therapeutic uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230731

R150 Certificate of patent or registration of utility model

Ref document number: 7329260

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150